BSE:524790

Stock Analysis Report

Executive Summary

Everest Organics Limited manufactures and sells pharmaceutical products in India.

Snowflake

Fundamentals

Outstanding track record with adequate balance sheet.

Risks

  • Everest Organics has significant price volatility in the past 3 months.
  • Everest Organics is not covered by any analysts.

Share Price & News

How has Everest Organics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

25.9%

BSE:524790

-1.3%

IN Pharmaceuticals

0.4%

IN Market


1 Year Return

86.2%

BSE:524790

-22.9%

IN Pharmaceuticals

-13.4%

IN Market

524790 outperformed the Pharmaceuticals industry which returned -21.6% over the past year.

524790 outperformed the Market in India which returned -12.8% over the past year.


Share holder returns

524790IndustryMarket
7 Day25.9%-1.3%0.4%
30 Day19.4%-1.4%-3.7%
90 Day2.3%-6.2%-7.4%
1 Year86.2%86.2%-22.1%-22.9%-11.7%-13.4%
3 Year280.8%280.8%-23.7%-25.3%18.7%12.4%
5 Yearn/a-6.4%-9.4%37.5%24.5%

Price Volatility Vs. Market

How volatile is Everest Organics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Everest Organics undervalued based on future cash flows and its price relative to the stock market?

14.41x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Everest Organics's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Everest Organics's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Everest Organics is good value based on earnings compared to the IN Pharmaceuticals industry average.

Everest Organics is overvalued based on earnings compared to the India market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Everest Organics, we can't assess if its growth is good value.


Price Based on Value of Assets

Everest Organics is overvalued based on assets compared to the IN Pharmaceuticals industry average.


Next Steps

Future Growth

How is Everest Organics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

-10.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Everest Organics is high growth as no revenue estimate data is available.

Everest Organics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.

Unable to compare Everest Organics's revenue growth to the India market average as no estimate data is available.

Everest Organics's earnings are expected to decrease over the next 1-3 years, this is below the India market average.

Everest Organics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 7.6%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Everest Organics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Everest Organics performed over the past 5 years?

46.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Everest Organics has delivered over 20% year on year earnings growth in the past 5 years.

Everest Organics's 1-year earnings growth exceeds its 5-year average (385.2% vs 46.4%)

Everest Organics's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (385.2% vs 16.6%).


Return on Equity

Everest Organics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Everest Organics used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Everest Organics has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Everest Organics's financial position?


Financial Position Analysis

Everest Organics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Everest Organics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Everest Organics's level of debt (81.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (555.2% vs 81.5% today).

Debt is not well covered by operating cash flow (19%, less than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 5.8x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 3.2x debt.


Next Steps

Dividend

What is Everest Organics's current dividend yield, its reliability and sustainability?

0.56%

Current Dividend Yield


Dividend Yield and Payments Analysis

Everest Organics's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.63%).

Everest Organics's dividend is below the markets top 25% of dividend payers in India (2.51%).

It is too early to tell whether Everest Organics has stable dividend payments.

Everest Organics only just started paying a dividend, it is too early to tell if payments are increasing.


Current Payout to Shareholders

Dividends paid are thoroughly covered by earnings (12.4x coverage).


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Everest Organics's salary, the management and board of directors tenure and is there insider trading?

11.9yrs

Average board tenure


CEO

Sri Raju (67yo)

3.6yrs

Tenure

₹3,000,000

Compensation

Dr. Sri Kakarlapudi Srihari Raju serves as the Managing Director since January 1, 2016 and Executive Director at Everest Organics and served as its Compliance Officer. 


CEO Compensation Analysis

Sri's remuneration is higher than average for companies of similar size in India.

Sri's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

11.9yrs

Average Tenure

59.5yo

Average Age

The average tenure for the Everest Organics board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

Buy₹1,317,02208 Jul 19
Bk Advance Research Llp
EntityCompany
Shares7,915
Max Price₹169.20

Ownership Breakdown


Management Team

  • Srikakarlapudi Krishna (40yo)

    Whole Time Director

    • Tenure: 11.9yrs
    • Compensation: ₹900.00k
  • Sri Raju (67yo)

    MD & Executive Director

    • Tenure: 3.6yrs
    • Compensation: ₹3.00m
  • Akella Parvatisem (52yo)

    Technical Director & Executive Director

    • Tenure: 15.0yrs
    • Compensation: ₹1.80m
  • Peruri Ramakrishna

    Chief Financial Officer

    • Tenure: 3.9yrs

Board Members

  • Sitaram Kakarlapudi (73yo)

    Non-Executive Director

    • Tenure: 0.0yrs
    • Compensation: ₹25.00k
  • Venkatesan Swaminathan

    Independent Non Executive Director

    • Tenure: 0.0yrs
    • Compensation: ₹75.00k
  • Kanthala Reddy (75yo)

    Non-Executive Director

    • Tenure: 0.0yrs
  • Srikakarlapudi Krishna (40yo)

    Whole Time Director

    • Tenure: 11.9yrs
    • Compensation: ₹900.00k
  • Kounparaju Raju

    Chairman

    • Tenure: 0.0yrs
    • Compensation: ₹85.00k
  • Sri Raju (67yo)

    MD & Executive Director

    • Tenure: 3.6yrs
    • Compensation: ₹3.00m
  • Akella Parvatisem (52yo)

    Technical Director & Executive Director

    • Tenure: 15.0yrs
    • Compensation: ₹1.80m
  • Sri Sirisha (42yo)

    Non-Executive Director

    • Tenure: 5.1yrs
    • Compensation: ₹55.00k
  • Sreeramakrishna Grandhi

    Independent Director

    • Tenure: 5.1yrs
    • Compensation: ₹45.00k

Company Information

Everest Organics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Everest Organics Limited
  • Ticker: 524790
  • Exchange: BSE
  • Founded: 1993
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹1.280b
  • Shares outstanding: 8.00m
  • Website: https://www.everestorganicsltd.com

Number of Employees


Location

  • Everest Organics Limited
  • Plot No.127 & 128
  • 1st Floor
  • Hyderabad
  • Andhra Pradesh
  • 500033
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524790BSE (Mumbai Stock Exchange)YesEquity SharesININRMar 2001

Biography

Everest Organics Limited manufactures and sells pharmaceutical products in India. It offers active pharmaceutical ingredients and intermediaries. The company also exports its products to Europe, the United ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 12:48
End of Day Share Price2019/08/20 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.